ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2294

Re-Scoring the 2011 Fibromyalgia Survey Criteria to be a Better Surrogate for Pain Centralization

Stephanie Moser1, Chad Brummett2, Alexander Tsodikov3, David A. Williams4 and Daniel J. Clauw2, 1Department of Anesthesiology, University of Michigan, Ann Arbor, MI, 2Anesthesiology, University of Michigan, Ann Arbor, MI, 3Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, 4Anesthseiology, University of Michigan, Ann Arbor, MI

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: fibromyalgia

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

The 2011 Fibromyalgia (FM) Survey Criteria is comprised of
measures of widespread pain (0-19 body areas) and 6 co-morbid symptoms (scored
0-12).  The measure has been termed “fibromyalgianess,” which Wolfe and others have shown to be
predictive of pain and disability in many rheumatic disorders.   We have shown that the continuous measure is
predictive of decreased opioid responsiveness and decreased improvement in pain
following arthroplasty, which we feel serves as a
marker of pain centralization.  We sought
to develop a new scoring method for the items that would improve the predictive
utility of the measure for centralized pain by re-weighting the existing items
to better predict failure to improve pain following arthroplasty. Methods:

457 knee or hip arthroplasty
patients were included. Changes in pain (WOMAC and Brief Pain Inventory (BPI))
from baseline to 6 months post-surgery and patient global impression of change
(PGIC) served as outcomes. A count of 7 body zones (head, spine, trunk, arms,
and legs) was compared to the count of 19 original body areas in 6 regression
models. Multiple regression models with the criteria items as predictors were
then conducted to determine item importance. 10-fold cross validation was used.
A new scale score was formed by weighting individual items that consistently
best predicted surgical outcomes.  Scale
scores were evaluated as predictors of surgical outcomes in regression models
in the development sample and a model testing sample of 391 other knee or hip arthroplasty patients. Performance was assessed with
R-square and AUROC.  Results:

The count of 7 body zones performed as well or better than
the original 19 body areas (Table 1). 
Thus the scoring using these zones was used in subsequent analyses. In
regression models, the body zones, headache, and trouble thinking were
consistently strong predictors of outcomes (Fig 1). The new scale score in
which headache and trouble thinking were weighted 2X and 3X times,
respectively, outperformed the original FM measure (Table 3). Conclusion:

This work provides evidence that the original FM Survey
Criteria can be re-scored to be a better predictor of poor response to arthroplasty.  Future
work is needed to determine the optimal manner to measure critical elements of
FM to define a new measure of pain centralization.




Disclosure: S. Moser, None; C. Brummett, Tonix Pharmaceuticals, 5; A. Tsodikov, None; D. A. Williams, Health Focus Inc., 5; D. J. Clauw, Abbott Laboratories, 5,Cerephex, 5,Eli Lilly and Company, 5,Forrest Laboratories, 5,Johnson & Johnson, 5,Merck Pharmaceuticals, 5,Pfizer Inc, 5,Purdue Pharma L.P., 5,Samumed, 5,Theravance, 5,Tonix, 5,UCB, 5,Zynerba, 5,Abbott Laboratories, 5,Cerephex, 5,Eli Lilly and Company, 5,Forest Laboratories, 5,Johnson & Johnson, 5,Merck Pharmaceuticals, 5,Pfizer Inc, 6,Purdue Pharma L.P., 6,Samumed, 5,Theravance, 5,Tonix, 5,UCB, 5,Zynerba, 5.

To cite this abstract in AMA style:

Moser S, Brummett C, Tsodikov A, Williams DA, Clauw DJ. Re-Scoring the 2011 Fibromyalgia Survey Criteria to be a Better Surrogate for Pain Centralization [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/re-scoring-the-2011-fibromyalgia-survey-criteria-to-be-a-better-surrogate-for-pain-centralization/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/re-scoring-the-2011-fibromyalgia-survey-criteria-to-be-a-better-surrogate-for-pain-centralization/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology